Drugs / ABP-745
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07303777 | Apr 2026 → Jan 2028 expected | atherosclerotic cardiovascular disease | Atom Therapeutics Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07145229 | Aug 2025 → May 2026 overdue | gout | Atom Therapeutics Co., Ltd | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06258213 Comparator | Jan → Jul 2024 | gout | Atom Therapeutics Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABP-745 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07303777 ↗ |
| Route | Oral | “following single (Part 1) and multiple (Part 2) oral doses” NCT06258213 ↗ |